Cover Image
市場調查報告書

Alkermes Plc 產品平台分析

Alkermes Plc - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 251771
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Alkermes Plc 產品平台分析 Alkermes Plc - Product Pipeline Review - 2014
出版日期: 2014年10月25日 內容資訊: 英文 48 Pages
簡介

Alkermes Plc 是總公司位於愛爾蘭的生物科技企業,正在研發、製造ADHD及依賴症的治療藥、高血壓、疼痛、多發性硬化症、肌肉痙攣、免疫疾病及糖尿病等慢性疾病的治療藥。

本報告提供Alkermes Plc 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Alkermes Plc 基本資料

  • Alkermes Plc 概要
  • 主要資訊
  • 企業資料

Alkermes Plc :R&D概要

  • 主要的治療範圍

Alkermes Plc :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Alkermes Plc :開發中產品概況

  • 後期階段產品開發中產品
    • 新藥登記前階段的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 臨床試驗前階段的產品/聯合治療模式

Alkermes Plc :藥物簡介

  • aripiprazole lauroxil
  • (samidorphan + buprenorphine hydrochloride)
  • (samidorphan + olanzapine)
  • ALKS-7106
  • ALKS-8700
  • samidorphan
  • olanzapine ER
  • RDB-1419

Alkermes Plc :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alkermes Plc :最新的開發平台資訊

Alkermes Plc :暫停開發的計劃

Alkermes Plc :開發中止的產品

Alkermes Plc :企業理念

Alkermes Plc :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06252CDB

Summary

Global Markets Direct's, 'Alkermes Plc - Product Pipeline Review - 2014', provides an overview of the Alkermes Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alkermes Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alkermes Plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alkermes Plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alkermes Plc's pipeline products

Reasons to buy

  • Evaluate Alkermes Plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alkermes Plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alkermes Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alkermes Plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alkermes Plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alkermes Plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alkermes Plc Snapshot
    • Alkermes Plc Overview
    • Key Information
    • Key Facts
  • Alkermes Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Alkermes Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alkermes Plc - Pipeline Products Glance
    • Alkermes Plc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Alkermes Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alkermes Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Alkermes Plc - Drug Profiles
    • aripiprazole lauroxil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (samidorphan + buprenorphine hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (samidorphan + olanzapine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALKS-7106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALKS-8700
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • samidorphan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (methylsamidorphan + opioid analgesic)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • olanzapine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RDB-1419
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alkermes Plc - Pipeline Analysis
    • Alkermes Plc - Pipeline Products by Target
    • Alkermes Plc - Pipeline Products by Route of Administration
    • Alkermes Plc - Pipeline Products by Molecule Type
    • Alkermes Plc - Pipeline Products by Mechanism of Action
  • Alkermes Plc - Recent Pipeline Updates
  • Alkermes Plc - Dormant Projects
  • Alkermes Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • insulin human
      • r-hFSH
      • samidorphan
      • teriparatide
  • Alkermes Plc - Company Statement
  • Alkermes Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alkermes Plc, Key Information
  • Alkermes Plc, Key Facts
  • Alkermes Plc - Pipeline by Indication, 2014
  • Alkermes Plc - Pipeline by Stage of Development, 2014
  • Alkermes Plc - Monotherapy Products in Pipeline, 2014
  • Alkermes Plc - Combination Treatment Modalities in Pipeline, 2014
  • Alkermes Plc - Partnered Products in Pipeline, 2014
  • Alkermes Plc - Partnered Products/ Combination Treatment Modalities, 2014
  • Alkermes Plc - Pre-Registration, 2014
  • Alkermes Plc - Phase III, 2014
  • Alkermes Plc - Phase II, 2014
  • Alkermes Plc - Phase I, 2014
  • Alkermes Plc - Preclinical, 2014
  • Alkermes Plc - Pipeline by Target, 2014
  • Alkermes Plc - Pipeline by Route of Administration, 2014
  • Alkermes Plc - Pipeline by Molecule Type, 2014
  • Alkermes Plc - Pipeline Products by Mechanism of Action, 2014
  • Alkermes Plc - Recent Pipeline Updates, 2014
  • Alkermes Plc - Dormant Developmental Projects,2014
  • Alkermes Plc - Discontinued Pipeline Products, 2014
  • Alkermes Plc, Other Locations
  • Alkermes Plc, Subsidiaries

List of Figures

  • Alkermes Plc - Pipeline by Top 10 Indication, 2014
  • Alkermes Plc - Pipeline by Stage of Development, 2014
  • Alkermes Plc - Monotherapy Products in Pipeline, 2014
  • Alkermes Plc - Combination Treatment Modalities in Pipeline, 2014
  • Alkermes Plc - Partnered Products in Pipeline, 2014
  • Alkermes Plc - Pipeline by Top 10 Target, 2014
  • Alkermes Plc - Pipeline by Top 10 Route of Administration, 2014
  • Alkermes Plc - Pipeline by Top 10 Molecule Type, 2014
  • Alkermes Plc - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top